STUDY OF THE INFLUENCE OF DIFFERENT TYPES OF STATINS IN THE TREATMENT OF ATHEROGENESIS
July 10, 2019
 |
Read full article |
| Article Title: | STUDY OF THE INFLUENCE OF DIFFERENT TYPES OF STATINS IN THE TREATMENT OF ATHEROGENESIS |
| Authors: | Osser Gyongyi1, Cecilia Avram4, Murg Sergiu2, Pletea Movileanu Ioana Maria3, Annamaria Pallag2, Hulbar Aurelia1, Maria Orodan4 |
| Affiliation: | 1″Vasile Goldiş” Western University, the Faculty of Pharmacy, Arad, L Rebreanu street 2The University of Oradea, the Faculty of Medicine, Pharmacy and Dental Medicine 3University of Medicine and Farmacy Carol Davila Bucharest 4″Vasile Goldiş” Western University, the Faculty of Medicine, Arad, L Rebreanu street |
| Abstract: | The discovery of statins has led to significant progress in both primary and secondary prevention of coronary heart disease. Although the angiographic changes following statin therapy were modest, the clinical benefits associated with therapy were significant. Numerous clinical trials have correlated the reduction in blood cholesterol induced by these compounds by reducing the number of major coronary events as well as reducing overall mortality in coronary patients |
| Keywords: | statins, UV spectrum, heart disease, cholesterol |
| References: | 1. Hunninghake D.B. – HMG-CoA reductase inhibitors, Curr. Opin. Lipidol., 1992, 3: 22-8 2. Ghinghină Carmen, Enache Roxana – Dislipidemia şi riscul cardiovascular: de la factorii clasici la noile fracţiuni lipidice, Stetoscop, Mai 2006, Anul 5, Nr. 50, pag. 20-23 3. Pârvulescu V-N, şi colab. – Dislipidemiile şi relaţia lor cu patologia generală, Practica Medicală, 2007, Vol. 2, Nr. 4(8), pag. 254-260 4. Rusu Emilia, Cheţa DM – Trigliceridele şi riscul cardiovascular, Stetoscop, Anul 6, Nr. 61, Aprilie 2007, pag. 16-20 5. Efthimiades A. – Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?, Angiology, 2008, 59: 62S-64S 6. Vaughan C.J., Gotto A.M., Basson C.T. – The evolving role of statins in the management of atherosclerosis, J. Am. Coll. Cardiol., 2000, 35: 1-10 7. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. – Non-lipid-related effects of statins, Ann. Med., 2000, 32: 164-176 8. Lennernas H., Fager G. – Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences, Clin. Pharmacokinet., 1997, 32: 403-425 9. Corsini A., Bellosta S., Baetta R., Fumagalli R., Bernini F. – New insights into the pharmacodynamics and pharmacokinetic properties of statins, Pharmacol. Ther., 1999, 84: 413-28 10. Sehayek E., Butbul E., Avner R. – Enhanced cellular metabolism of very low density lipoprotein by simvastatin: a novel mechanism of action of HMG-CoA reductase inhibitors, Eur. J. Clin. Invest., 1994, 24: 173-8 11. Blum C.B. – Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Am. J. Cardiol., 1994, 73: 3D-11D 12. Rizzo M., Rini GB, Berneis R. – Effects of statins, fibrates, rosuvastatin and ezetimibe beyond cholesterol: the modulation of LDL size and subcalsses in high-risk patients, Adv. Ther., 2007, 575-582 13. Thavendiranathan P., bagal A., Brookhart A., et al. – Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials, Arch. Intern. Med., 2006, 166: 2307-2313 14. Afilalo J., Majdan AA, Eisenberg MJ – Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials, Heart, 2007, 93: 914-921 15. Fauchier L., Pierre B., de Labriolle A., et al – Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials, J. Amer. Coll. Cardiol., 2008, 51: 828-835 16. Blumenthal RS. – Statins: effective antiatherosclerotic therapy, Am. Heart. J., 2000, 139: 577-83 17. Kostner G.M., Gavish D., Leopold B., Bolzano K., Weintraub M.S., Breslow J.L. – HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels, Circulation, 1989, 80: 1313-1319 18. Stein E.A., Lane M., Laskarzewski P. – Comparison of statins in hypertriglyceridemia, Am. J. Cardiol., 1998, 81: 66B-69B 19. Gaw A., Packard C.J., Murray E.F. – Effects of simvastatin on apoB metabolism and LDL subfraction distribution, Arterioscler. Thromb., 1993, 13: 170-89 20. Marais A.D., Naumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. – Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia, J. Lipid Res., 1997, 38: 2071-2078 21. Raal F.J., Pilcher G.J., Illingworth D.R., Pappu A.S., Stein E.A., et al. – Expanded dose simvastatin is effective in homozygous familial hypercholesterolemia, Atherosclerosis, 1997, 135: 249-256 22. Hoffman R., Brook G.J., Aviram M. – Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies, Atherosclerosis, 1992, 93: 105-13 23. Chen L., Haught W.H., Yang B. – Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine, J. Am. Coll. Cardiol., 1997, 30: 569-75 24. Aviram M., Hussein O., Rosenblat M., Schlezinger S., Hayek T., Keidar S.- Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy, J. Cardiovasc. Pharmacol., 1998, 31: 39-45, 25. Pietsch A., Erl W., Lorenz R.L. – Lovastatin reduces the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells, Biochem. Pharmacol., 52: 433, 1996 26. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. – Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages, Atherosclerosis, 1993, 104: 19-26 27. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R. – HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler. Thromb. Vasc. Biol., 1998, 18: 1671-8 28. Ballantyne C.M., Herd J.A., Dunn J.K., Jones P.H., Farmer J.A., Gotto A.M.J. – Effects of lipid lowering therapy on progression of coronary and carotid artery disease, Curr. Opin. Lipidol., 1997, 8: 354-361 29. Libby P. – Atherosclerosis: the new view, Sci. Amer., 2002, 286: 47-55 30. Libby P. – The molecular mechanisms of the thrombotic complications of atherosclerosis, J. Intern. Med., 2008, 263: 517-527 |
| *Correspondence: | annamariapallag@yahoo.com |
About The Author
